Atlas Trials

Nanjing Immunophage Biotech Co., Ltd

9 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Nanjing Immunophage Biotech Co., Ltd

RecordFirmDate
Efficacy and Safety of IPG11406 in Moderately to Severely Active Ulcerative Colitis (Phase 2) (NCT07535489)Nanjing Immunophage Biotech Co., Ltd2026-07-07
IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors (NCT07508761)Nanjing Immunophage Biotech Co., Ltd2026-06-16
Phase IIa Study for IPG11406 in Patients With Lupus Nephritis (NCT06717815)Nanjing Immunophage Biotech Co., Ltd2025-02-25
Phase I/II Study of IPG1094 in Advanced Solid Tumors Patients (NCT06212076)Nanjing Immunophage Biotech Co., Ltd2024-07-11
Phase 1 Study for IPG11406 in Health Volunteer (NCT06255834)Nanjing Immunophage Biotech Co., Ltd2024-02-24
A Study of Orally Administered IPG7236 in Healthy Adult Participants (NCT05288543)Nanjing Immunophage Biotech Co., Ltd2022-04-07
Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors (NCT05142592)Nanjing Immunophage Biotech Co., Ltd2021-11-15
Phase 1 Study of IPG1094 Safety, Tolerability, and PK in Healthy Participants (NCT05112159)Nanjing Immunophage Biotech Co., Ltd2021-09-27

Track Nanjing Immunophage Biotech Co., Ltd automatically

Every clearance here is in the API, with alerts when new ones post.